Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
about
Pharmacology of proton pump inhibitorsComparative efficacy of rabeprazole and pantoprazole in the control of nocturnal Acid output and intragastric acidity.Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazoleClinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects.Validation and application of a new reversed phase HPLC method for in vitro dissolution studies of rabeprazole sodium in delayed-release tablets.A second-look endoscopy may not reduce the bleeding after endoscopic submucosal dissection for gastric epithelial neoplasm.Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy.Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: A comparative study of efficacy and safetyReview of rabeprazole in the treatment of gastro-oesophageal reflux disease.Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease.Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.Review article: gastric pH -- the most relevant predictor of benefit in reflux disease?Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.Efficacy of esomeprazole in treating acid-related diseases in Japanese populationsReview article: similarities and differences among delayed-release proton-pump inhibitor formulations.Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.Therapeutic options in the treatment of nighttime gastroesophageal reflux.Review article: intragastric and oesophageal pH monitoring in patients with gastro-oesophageal reflux disease.Acid suppression therapy: where do we go from here?A review of rabeprazole in the treatment of acid-related diseasesPotential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole.CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus.Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole.Rabeprazole for the treatment of acid-related disorders.Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines.Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole?Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment.Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole.Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study.A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study.Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects.A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers.
P2860
Q24634771-16BE6800-6E72-4AFC-83D4-CBF1E42E1FF8Q33855564-2F6F4DCE-DE2D-4C3D-A2AA-00CEE15C36A7Q33868511-90447A2E-FDF0-4045-A4C4-836CC8FCFBFBQ33946261-48B981BD-D80F-4A4D-AFFD-08920C25A538Q34140776-93AB7F39-0AB7-4D39-9E3A-EA0E65659E99Q34373065-0C34E082-8CD1-4EC3-9C6F-885EDCC12AB4Q35004535-83262176-F974-41FB-9C51-17600FCDAE74Q35010979-F59F6210-880E-4183-9CC1-AFF233FC4353Q35011405-33B21AB8-2549-4115-B202-5CEC4D1FBC88Q35167717-44021991-D1DC-4749-BD77-1BB5E20B3016Q35609697-16BCC0B2-E344-4AC6-BD14-22B8152AD3B2Q35857847-2459476A-068C-47B1-B6E3-B9B12F7C4252Q35868527-EA838305-3BA6-4314-B79F-0392EC79F30FQ35904901-00FD8817-274F-4DC1-85C9-EB572962BF04Q35923949-D62AE152-E861-4308-AE00-9B1AF0AE7D2AQ35923954-5A35ADD8-B794-4AEA-9BD3-5670A93BDEA1Q35923964-9D23AB27-28B3-49C2-BCD1-26585780ECA8Q35987201-9D2EFE88-8AEE-4B68-80F1-6058B2ADFA88Q36319527-5AE8944A-EEC3-4B96-96FD-723DA0A46782Q36322095-FF35DEA3-0B88-4BB1-A669-4FA64AF7919EQ36327508-A871BDB3-8808-4196-AC0C-56006EC5C9B3Q36398669-BA2E7551-21BD-4295-9EB1-61167C0095AEQ36478082-BDCB9C39-1407-46E5-80BF-03EC8F5FDE90Q36661321-F4F6E388-220A-4C9C-98B0-7830AF9AB785Q37018462-E79F4595-0A1D-435F-ACA1-B17FEB22E441Q37248763-5BDDB362-A0B3-4DB8-A68F-4FC3F355B1D0Q37646785-57BC0B48-904C-41A1-9E64-8B4498B5B0F3Q37709906-4FEED2E8-328B-47E5-BD37-72AD12D25139Q37808356-63969EE6-D539-45C8-8E32-A96C9738897FQ38038691-A866565A-17AD-45B3-A16F-A97B73AE929CQ38958255-EF5A6EFC-5EDB-400A-814B-4D3079713418Q39345800-E561878F-7B5F-4F11-B80B-298B13AFCCA7Q39345807-1BBAF22A-04AD-4E41-96B5-7D80A3535571Q39368773-5DC3D8E0-B44E-486B-B767-CA64A454CA3BQ39378798-E2197E39-D54D-4BC9-9A83-0D8FD2BD799EQ41120052-B40A6B32-671F-4A10-9177-5512FB4A6B76Q42868371-FF277446-CB5D-4B9C-8567-3B4BF7C6D661Q44600156-36632FF8-A156-4737-A218-C074B70E0BA5Q45103019-47BAA4F5-A27D-461B-8C00-62DE29CE3055Q45289833-40C54E10-CFBE-4833-9C7E-4FD8C5D6A5AA
P2860
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
@en
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
@nl
type
label
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
@en
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
@nl
prefLabel
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
@en
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
@nl
P2093
P2860
P1476
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2036.2003.01496.X
P407
P577
2003-06-01T00:00:00Z